News

We are pleased to announce that MAHTA is a content partner of the 12th Scientific Conference under the patronage of the renowned Journal of Health Policy and Outcomes Research. This year's edition will be an opportunity to explore key issues and challenges facing health policy in Poland and around the world in 2025. The MAHTA team will present two topics in the presentation section. Director Karolina Dziadek will present "Systemic and clinical benefits of financing assisted dialysis in patients requiring renal replacement therapy in Poland", and Dr. Michał Jachimowicz will discuss "The cost-effectiveness of multigene testing in prognostic and predictive assessment of the benefit of chemotherapy in patients with early invasive breast cancer, using the example of Oncotype DX - from a Polish and European perspective". We cordially invite you to attend this event.

Merry Christmas and a Happy New Year.

We are proud to announce that the MAHTA Team will be attending this year's PTFe conference, a key event for the healthcare sector, which will take place on November 27-29, 2024. As every year, our co-owner, Michał Jachimowicz, will have the honor of co-hosting this important gathering, bringing his expertise and insights to the table.

We are also excited to share that our colleague, Karolina Dziadek, will be presenting the poster: "Replacement Therapy: Comparison of peritoneal dialysis with haemodialysis – results of an economic analysis''.

It is a great opportunity to discuss advancements, share knowledge, and connect with professionals who are shaping the future of healthcare.

See you soon at PTFe!

MAHTA Team is proud to announce that we will be presenting six posters at the ISPOR Europe 2024 conference in Barcelona.

These posters will showcase the latest research and innovative approaches in Health Economics and Outcomes Research (HEOR), Market Access and Health Technology Assessment (HTA). We look forward to sharing our findings and contributing to the ongoing discussions on improving healthcare outcomes around the world.

We invite all attendees to visit our poster presentations and engage with our experts. Let's get in touch and explore opportunities for cooperation.

See you in Barcelona!

We are pleased to announce that the MAHTA Team attended this year's HTAi in Seville, Spain. Three exceptional abstracts prepared by our Team were presented as posters during this event.

We are very pleased to announce the poster presentation at this year's European Society of Endocrinology conference in Stockholm. The MAHTA Team, in cooperation with Recordati Rare Disease, Lumanity and Professor Rosario Pivonello, demonstrated in the eagerly awaited paper by the endocrinology community, 'Comparative efficacy and safety of osilodrostat versus metyrapone for the treatment of Cushing's syndrome - a matching-adjusted indirect comparison using LINC-3 and LINC-4', that osilodrostat increased the odds of achieving a complete response at weeks 12, 24 and 36 compared to metyrapone, proving that osilodrostat is a more effective treatment option than metyrapone in normalising cortisol levels in patients with Cushing's syndrome.

We invite you to read the abstract in the link below: Comparative efficacy and safety of osilodrostat vs metyrapone for the treatment of Cushing’s syndrome – a matching-adjusted indirect comparison using LINC-3 and LINC-4 | ECE2024 | 26th European Congress of Endocrinology | Endocrine Abstracts (endocrine-abstracts.org) here: link do the website.

We would like to wish all of our Customers, Partners and Colleagues a peaceful and happy Easter!

The celebration of World Rare Disease Day, organised by the National Forum for Rare Disease Therapy ORPHAN, took place on 29.02.24–1.03.204. The MAHTA team has been involved for many years in activities aimed at increasing the availability of reimbursed orphan drugs on the Polish and international markets. We are therefore grateful for the opportunity to participate in this special event. During the conference "Rare diseases – diagnosis and drugs dedicated to their therapy – challenges for Poland 2024", Dr Michal Jachimowicz, representing the MAHTA team, was one of the speakers of the session on systemic and pharmacoeconomic challenges for rare diseases - MCDA.

We are very pleased to announce that the American Journal of Gastroenterology has published the abstract of "Savings in Social Expenditures for Work Incapacity in Patients With Inflammatory Bowel Disease Depend on Access to Innovative Therapies in Poland", co-authored by the MAHTA team.

We encourage you to read the abstract at the following link: S109 Savings in Social Expenditures for Work Incapacity in P... : Official journal of the American College of Gastroenterology | ACG (lww.com) link to the website.

Dear Clients, Partners and Friends,

We are wishing you Happy Holidays and a Wonderful New Year!

The latest report, prepared by the MAHTA Company, in cooperation with Prof. Edyta Zagórowicz, MD and Prof. Jaroslaw Regula, MD, under the auspices of the Polish Society of Gastroenterology and the PRO MEDICINA Foundation, concerns the social burden associated with inflammatory bowel diseases in Poland. The aim of the report was to resolve whether the chosen direction of changes in the approach to financing the treatment of IBD, which includes the increasing reimbursement of innovative drugs, brings substantial benefits also from the perspective of public spending. This is the first report of its kind in Poland.

We invite you to read the report, which is available here: link to the website.

We are proud to present one of our latest reports, which was prepared in collaboration with prominent experts in the fields of molecular diagnostics, clinical oncology and health care system in Poland. The report points to the need to implement routine evaluation of BRCA1/2 gene mutations in every breast cancer patient. Its assumptions include specific recommendations for making changes to the current diagnostic algorithm.

We invite and encourage you to read the full TEXT. Link to the website.

We are extremely pleased to announce that the MAHTA team will participate in CNFMS 2023 - Romanian National Conference of Pharmacoeconomics and Health Management in Poiana Brașov.

We are pleased to announce that two posters, co-authored by the MAHTA Intl. team, were presented at this year's 25th European Congress of Endocrinology. The first one: ,,Health state utility value of Cushing syndrome patients after bilateral adrenalectomy–systematic literature review and mapping to EQ-5D’’ considers quality of life of patients with CS after BLA. Second poster: ,,Comparative Efficacy and Safety of Osilodrostat vs Metyrapone for the Treatment of Cushing’s Syndrome – a Matching-Adjusted Indirect Treatment Comparison’’ presents a high-quality clinical comparison of two steroidogenesis inhibitors, osilodrostat and metyrapone using patient-level data. Congratulations to the authors.

During ISPOR 2023 conference in Boston a poster ‘’Cost-Effectiveness Analysis of Pasireotide Long-Acting Release As a Second Line Treatment for Adult Acromegaly Patients‘’, co-authored by a member of MAHTA Intl. was presented. The study evaluates the cost-effectiveness of second line treatments of acromegaly in adults for whom surgery is no option or has not been curative and who were previously inadequately controlled with somatostatin receptor ligands. The analysis showed that pasireotide LAR provides significant health benefits to acromegaly patients. With limited options for second-line medical treatment, the reimbursement of pasireotide LAR in acromegaly is crucial.

The poster is available at the link: here.

We are proud to announce that from 10th to 14th of November MAHTA participated in the pharmacoeconomic conference ISPOR Europe 2018 in Barcelona. ISPOR (International Society for Pharmaeconomics and Outcomes Research) is the leading global scientific organization for researchers, academics and students interested in pharmacoeconomics. During the poster session MAHTA’s analysts presented de novo pharmacoeconomic model and analysis results of Noqturina® in the treatment of nocturia caused by nocturnal polyuria. We invite you to read the poster.

Within the days 10 – 14 of November 2018 the next ISPOR Conference (International Society For Pharmacoeconomics and Outcomes Research) is about to take place, this time as “New Perspectives of healthcare systems enhancement in the XXI century”.

This year, the ISPOR Europe Conference will be held in Barcelona, where all the professionals connected to HEOR (Health Economics and Outcomes Research), which is particularly aimed at familiarizing experts with new trends and conclusions drowned up from pharmacoeconomics and clinical outcomes researches.

MAHTA is about to participate in the Conference actively, presenting its poster with pharmacoeconomic model outcomes conducted for an important disease in Poland.

https://www.ispor.org/conferences-education/conferences/upcoming-conferences/europe-2018

1st session:

Risk sharing schemes (RSS): new possibilities available according to Law on reimbursement, effective price depending on RSS type, how RSS can affect the effective price. Speaker: Grzegorz Binowski, MAHTA

2nd session:

Indirect comparison and network metaanalysis – methodology and credibility of new methods indicated in Polish HTA Guidelines. Speakers: Agnieszka Kalinowska, Marta Kowalczyk, MAHTA.

More information is available here (http://www.ispor2016.pl/?p=60)

Urodynamic study is no longer necessary to gain reimbursed drugs for overactive bladder (OAB) treatment.

Urodynamic test was on official requirement in order to be prescribed reimbursed treatment for OAB – Poland was the only country where such limitation was imposed. Patients had been trying to cancel this requirement since 2011. This restrictions was lifted on 1 July 2016.

Health Technology Assessment report in this health problem was made by MAHTA.

The report is available here: link to the website.

Drug reimbursement list is available here: link to the website.

The Transparency Council and the President of the Agency for Health Technology Assessment and Tariff System (AOTMiT) recommend reimbursement of Humira® (adalimumab) for treatment of adults with severe axial spondyloarthritis without radiographic evidence of ankylosing spondylitis. Adalimumab demonstrated efficacy and the results of pharmacoeconomic analyses (provided by MAHTA) were favorable.

Currently, the treatment in this indication is not reimbursed in Poland. It should be emphasized that TNF-alpha inhibitors, such as adalimumab, are the current standard of care for patients with axial spondyloarthritis without radiographic evidence of ankylosing spondylitis. Adalimumab is reimbursed in most European Union countries, including some countries with similar to Polish level of GDP per capita.

Download Recommendation here: link to the website.

Access to innovative cancer therapies is currently limited in Poland. There are few new anticancer therapies on the list of reimbursed drugs and the reimbursement procedure usually takes several months. Therefore, taking into account the patients’ needs, a group of experts issued a report proposing activities aimed at raising funds for oncological treatments without public payer involvement. The report is referred to as the Polish Cancer Drugs Fund (FWR). The presented solutions enable the treatment with innovative drugs within a short period after their registration.

Cezary Pruszko and Agnieszka Kalinowska, as MAHTA representatives, are the co-authors of this report.

Download the report here: link to file.

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) organizes ISPOR 21st Annual International Meeting which would be held during May 21-25, 2016 in Washington. MAHTA is pleased to present a poster concerning the results of the economic analysis which was prepared for budesonide MMX® in treatment of ulcerative colitis of mild to moderate severity. The poster presents the key assumptions and results made in our economic analysis (Pruszko C., Kowalczyk M., Książek P. et al.): Economic implications of budesonide MMX® advantage in ulcerative colitis treatment over systemic steroids: budesonide MMX® decreases ulcerative colitis treatment costs.

Click for more information: link to the website.